Company Overview and News
Mitsubishi UFJ Financial Group (MUFG - Free Report) is scheduled to report first-quarter fiscal 2018 (ended Jun 30, 2018) results on Aug 2. This Japan-based banking giant reported profits attributable to owners of parent of ¥989.6 billion ($8.9 billion) for fiscal 2017, up 6.8% year over year. Results reflected low credit costs and strong capital as positives. Nevertheless, elevated general & administrative expenses, decreased gross profits and decline in net interest income acted as headwinds.
BRK.A RY RY BNS 8306 MUFG MBFJF MTU BNS
This is the fourth month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $1,319.70.
GIS CAT WBA ENB OPRF JCI HSY ABBV MMM POL MO DUKH GD TRV MAIN CMI ENB RY BNS JNJ TROW VZ WPC ABBV MSFT ADM PFE PM PFBC SCL IRET CTL OXLCM OXLCO TD ETN OXLCN BNS CM MSCA INTC TD IBM RY TNTTF LYB MSB O DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL CBL
PowerShares Exchange-Trade Fund Trust (NASDAQ:PXI) has 35 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 774,411 shares. Largest shareholders include Invesco Ltd., Morgan Stanley, Bank Of America Corp /de/, Commonwealth Equity Services, Llc., Jane Street Group, Llc, Raymond James Financial Services Advisors, Inc.
PXE PBS PKB PSJ PDP PSI MS PGF PUI PSP PWT BAC PBJ PWY PWB PXI RY PWJ PWP PTF PTH WFCNP PJG PJF PUW PRN PJM PEJ PMR PFM RBCDF PZI PFI BAC PIV PSL WFC PYZ RY PID PNQI PXJ PXQ IVZ PEZ
Xplore Technologies Corp. (NASDAQ:XPLR) has 41 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,969,856 shares. Largest shareholders include Phoenix Venture Fund LLC, Merriman Wealth Management, LLC, Royal Bank Of Canada, Vanguard Group Inc, Renaissance Technologies LLC, AWM Investment Company, Inc.
XPLR RY RY VRX ZBRA RBCDF SLXP PGNX
Deutsche Bank’s (DB - Free Report) U.S. subsidiary, DB USA Corporation (“DBUSA”) has failed the second level of the Federal Reserve’s stress test on qualitative basis. This is the first time that DBUSA publicly participated in the comprehensive capital analysis and review program.
DB RY RY UBS ULSGF
The Fed will be announcing the results of bank stress tests on Jun 21 and results of its Comprehensive Capital Analysis Review ("CCAR") on Jun 28. The tests, which are an annual affair and a must for banks since the 2008 financial meltdown, are designed to ensure that they are in a healthy position to handle crisis during an economic downturn. Looking back, President Donald Trump in May signed the biggest rollback of bank regulations since the global economic downturn into law.
BNPQY 83SF GLSSP DBXFF 83SK STI-A MS DBFBF CSSLF DBAGF BNPZY DBZQF DBTMF DB DGLD CS BAC DBCBW DBQFF 47MC RY VIIX GSC VIIZ BNPQF DBZFF GSJ CSGKF TVIX GJS ULSGF DBWQF XIV DBFFF BCS UGLD DBCQF BBT JBK BAC DSLV TFG DBFMF DBWGF RY STI CGBBW WFCNP DBQZF DBWFF GS UBS WFC C DBYQF ZIV USLV
This is the third month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $891.57.
GIS WBA ENB OPRF JCI HSY ABBV MMM POL MO SMG DUKH GD TRV MAIN BX CMI ENB RY BNS JNJ TROW GPT VZ ABBV MSFT WPC ADM PFE CLX PM PFBC SKT SCL CTL IRET OXLCM OXLCO TD ETN OXLCN BNS CM MSCA INTC TD IBM RY TNTTF LYB O MSB DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL BMRC DLR CBL
Evofem Biosciences, Inc. (NASDAQ:EVFM) has 11 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 14,524,670 shares. Largest shareholders include Woodford Investment Management LLP, Invesco Ltd., Millennium Management Llc, Panagora Asset Management Inc, Bank Of America Corp /de/, BlackRock Inc.
EVFM BAC RY PTLA GALPW RBCDF STML BAC BLK RY UBS VBLT GALE VBLTF ULSGF GALEW IVZ
2018-08-13 - Asif
Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...
2018-08-13 - Asif
Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...
2018-08-13 - Asif
Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...